176 related articles for article (PubMed ID: 11298704)
1. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis.
Kantor J; Margolis DJ
Dermatol Surg; 2001 Apr; 27(4):347-51. PubMed ID: 11298704
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
Persson U; Willis M; Odegaard K; Apelqvist J
Value Health; 2000; 3 Suppl 1():39-46. PubMed ID: 16464208
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
Ghatnekar O; Persson U; Willis M; Odegaard K
Pharmacoeconomics; 2001; 19(7):767-78. PubMed ID: 11548912
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
Sibbald RG; Torrance G; Hux M; Attard C; Milkovich N
Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
[TBL] [Abstract][Full Text] [Related]
5. Cost-effective management of recalcitrant diabetic foot ulcers.
Albert S
Clin Podiatr Med Surg; 2002 Oct; 19(4):483-91. PubMed ID: 12471856
[TBL] [Abstract][Full Text] [Related]
6. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers.
Langer A; Rogowski W
BMC Health Serv Res; 2009 Jul; 9():115. PubMed ID: 19591680
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
Wieman TJ; Smiell JM; Su Y
Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
[TBL] [Abstract][Full Text] [Related]
8. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers.
Papanas N; Maltezos E
Clin Interv Aging; 2008; 3(2):233-40. PubMed ID: 18686746
[TBL] [Abstract][Full Text] [Related]
9. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
Nagai MK; Embil JM
Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
Smiell JM; Wieman TJ; Steed DL; Perry BH; Sampson AR; Schwab BH
Wound Repair Regen; 1999; 7(5):335-46. PubMed ID: 10564562
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
Embil JM; Papp K; Sibbald G; Tousignant J; Smiell JM; Wong B; Lau CY
Wound Repair Regen; 2000; 8(3):162-8. PubMed ID: 10886806
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers.
Gilligan AM; Waycaster CR; Motley TA
Wound Repair Regen; 2015; 23(3):353-60. PubMed ID: 25810233
[TBL] [Abstract][Full Text] [Related]
13. Use of Regranex gel for diabetic foot ulcers.
Piascik P
J Am Pharm Assoc (Wash); 1998; 38(5):628-30. PubMed ID: 9782698
[No Abstract] [Full Text] [Related]
14. Cost-Effectiveness of Becaplermin Gel on Diabetic Foot Ulcer HealingChanges in Wound Surface Area.
Waycaster CR; Gilligan AM; Motley TA
J Am Podiatr Med Assoc; 2016 Jul; 106(4):273-82. PubMed ID: 27049838
[TBL] [Abstract][Full Text] [Related]
15. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers.
Papanas N; Maltezos E
Drug Saf; 2010 Jun; 33(6):455-61. PubMed ID: 20486728
[TBL] [Abstract][Full Text] [Related]
16. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
Rees RS; Robson MC; Smiell JM; Perry BH
Wound Repair Regen; 1999; 7(3):141-7. PubMed ID: 10417749
[TBL] [Abstract][Full Text] [Related]
17. Hyperbaric Oxygen Therapy for the Treatment of Diabetic Foot Ulcers: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2017; 17(5):1-142. PubMed ID: 28572866
[TBL] [Abstract][Full Text] [Related]
18. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management.
Boykin JV
Adv Skin Wound Care; 2000; 13(4 Pt 1):169-74. PubMed ID: 11075012
[TBL] [Abstract][Full Text] [Related]
19. The importance of growth factors for the treatment of chronic wounds in the case of diabetic foot ulcers.
Buchberger B; Follmann M; Freyer D; Huppertz H; Ehm A; Wasem J
GMS Health Technol Assess; 2010 Sep; 6():Doc12. PubMed ID: 21289885
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study.
Guzman-Gardearzabal E; Leyva-Bohorquez G; Salas-Colín S; Paz-Janeiro JL; Alvarado-Ruiz R; García-Salazar R
Adv Ther; 2000; 17(4):184-9. PubMed ID: 11185057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
